Cara Therapeutics, Inc. (CARA) - EV/EBITDA Multiple

The daily price chart for Cara Therapeutics, Inc. (CARA) shows an EV/EBITDA multiple of 0.00. The business model relies on licensing its proprietary developments to major industry players, which eliminates capital expenditures. In the competition for the neuro-drug market, Cara Therapeutics, Inc. (CARA) is betting on the exclusivity of its formulas. Currently, R&D activity is temporarily reduced, with resources focused on cost optimization and the support of existing licenses.
Comprehensive metric breakdowns and analytics for Cara Therapeutics (CARA)

For the biotechnology sector company Cara Therapeutics, Inc. (CARA), this indicator serves as a tool for assessing the real value of assets while accounting for debt load and tax obligations. The Enterprise Value to EBITDA ratio compares the total market price of the business with its operating profit before depreciation and amortization, eliminating the influence of capital structure. This chart's dynamics allow investors to evaluate the monetization efficiency of the company's patent developments and strategic partnerships.